Literature DB >> 23404464

Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.

Kui Wu1, Wenbing Hu, Qun Luo, Xianchan Li, Shaoxiang Xiong, Peter J Sadler, Fuyi Wang.   

Abstract

We report identification of the binding sites for an organometallic ruthenium anticancer complex [(η (6)-biphenyl)Ru(en)Cl][PF6] (1; en = ethylenediamine) on the 15-mer single-stranded oligodeoxynucleotides (ODNs), 5'-CTCTCTX7G8Y9CTTCTC-3' [X = Y = T (I); X = C and Y = A (II); X = A and Y = T (III); X = T and Y = A (IV)] by electrospray ionization mass spectrometry (ESI-MS) in conjunction with enzymatic digestion or tandem mass spectrometry (top-down MS). ESI-MS combined with enzymatic digestion (termed MS-based ladder-sequencing), is effective for identification of the thermodynamically-favored G-binding sites, but not applicable to determine the thermodynamically unstable T-binding sites because the T-bound adducts dissociate during enzymatic digestion. In contrast, top-down MS is efficient for localization of the T binding sites, but not suitable for mapping ruthenated G bases, due to the facile fragmentation of G bases from ODN backbones prior to the dissociation of the phosphodiester bonds. The combination of the two MS approaches reveals that G8 in each ODN is the preferred binding site for 1, and that the T binding sites of 1 are either T7 or T11 on I and IV, and either T6 or T11 on II and III, respectively. These findings not only demonstrate for the first time that T-bases in single-stranded oligonucleotides are kinetically competitive with guanine for such organoruthenium complexes, but also illustrate the relative merits of the combination of ladder-sequencing and top-down MS approaches to elucidate the interactions of metal anticancer complexes with DNA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404464     DOI: 10.1007/s13361-012-0539-z

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  41 in total

Review 1.  Recent developments in mass spectrometry for the characterization of nucleosides, nucleotides, oligonucleotides, and nucleic acids.

Authors:  Joseph H Banoub; Russell P Newton; Eddy Esmans; David F Ewing; Grahame Mackenzie
Journal:  Chem Rev       Date:  2005-05       Impact factor: 60.622

2.  Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex.

Authors:  Hong-Ke Liu; Susan J Berners-Price; Fuyi Wang; John A Parkinson; Jingjing Xu; Juraj Bella; Peter J Sadler
Journal:  Angew Chem Int Ed Engl       Date:  2006-12-11       Impact factor: 15.336

3.  Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.

Authors:  Kui Wu; Qun Luo; Wenbing Hu; Xianchan Li; Fuyi Wang; Shaoxiang Xiong; Peter J Sadler
Journal:  Metallomics       Date:  2012-01-20       Impact factor: 4.526

4.  Mass spectrometry of nucleic acids.

Authors:  E Nordhoff; F Kirpekar; P Roepstorff
Journal:  Mass Spectrom Rev       Date:  1996       Impact factor: 10.946

Review 5.  Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins.

Authors:  J L Beck; M L Colgrave; S F Ralph; M M Sheil
Journal:  Mass Spectrom Rev       Date:  2001 Mar-Apr       Impact factor: 10.946

6.  Interpretation of oligonucleotide mass spectra for determination of sequence using electrospray ionization and tandem mass spectrometry.

Authors:  J Ni; C Pomerantz; J Rozenski; Y Zhang; J A McCloskey
Journal:  Anal Chem       Date:  1996-07-01       Impact factor: 6.986

7.  Fragmentation of electrospray-produced oligodeoxynucleotide ions adducted to metal ions.

Authors:  Y Wang; J S Taylor; M L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2001-05       Impact factor: 3.109

8.  Inhibition of cancer cell growth by ruthenium(II) arene complexes.

Authors:  R E Morris; R E Aird; P del S Murdoch; H Chen; J Cummings; N D Hughes; S Parsons; A Parkin; G Boyd; D I Jodrell; P J Sadler
Journal:  J Med Chem       Date:  2001-10-25       Impact factor: 7.446

9.  Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

Authors:  Haimei Chen; John A Parkinson; Robert E Morris; Peter J Sadler
Journal:  J Am Chem Soc       Date:  2003-01-08       Impact factor: 15.419

10.  High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.

Authors:  Alexander E Egger; Christian G Hartinger; Hisham Ben Hamidane; Yury O Tsybin; Bernhard K Keppler; Paul J Dyson
Journal:  Inorg Chem       Date:  2008-10-24       Impact factor: 5.165

View more
  6 in total

Review 1.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

Review 2.  The multifaceted roles of mass spectrometric analysis in nucleic acids drug discovery and development.

Authors:  Thomas Kenderdine; Dan Fabris
Journal:  Mass Spectrom Rev       Date:  2021-12-23       Impact factor: 9.011

3.  Ruthenation of Non-stacked Guanines in DNA G-Quadruplex Structures: Enhancement of c-MYC Expression.

Authors:  Jéssica Rodríguez; Jesús Mosquera; José R Couceiro; M Eugenio Vázquez; José L Mascareñas
Journal:  Angew Chem Int Ed Engl       Date:  2016-11-17       Impact factor: 15.336

Review 4.  Targeting of the intracellular redox balance by metal complexes towards anticancer therapy.

Authors:  María Isabel Murillo; Christian Gaiddon; Ronan Le Lagadec
Journal:  Front Chem       Date:  2022-08-11       Impact factor: 5.545

5.  Binding of Organometallic Ruthenium Anticancer Complexes to DNA: Thermodynamic Base and Sequence Selectivity.

Authors:  Suyan Liu; Aihua Liang; Kui Wu; Wenjuan Zeng; Qun Luo; Fuyi Wang
Journal:  Int J Mol Sci       Date:  2018-07-23       Impact factor: 5.923

6.  p-Cymene Complexes of Ruthenium(II) as Antitumor Agents.

Authors:  María Angeles Pujante-Galián; Sergio A Pérez; Mercedes G Montalbán; Guzmán Carissimi; Marta G Fuster; Gloria Víllora; Gabriel García
Journal:  Molecules       Date:  2020-10-31       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.